CCL3/MIP-1α (F3I3P) Rabbit mAb #43710
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 10 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
CCL3/MIP-1α (F3I3P) Rabbit mAb recognizes endogenous levels of total CCL3/MIP-1α protein. This antibody does not cross-react with CCL4 or CCL18 proteins.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro43 of human CCL3/MIP-1α protein.
Background
Chemokine (C-C motif) ligand 3 (CCL3), also known as macrophage inflammatory protein-1α (MIP-1α), is a 10 kDa member of the C-C or β family of chemokines that play key roles in immune surveillance, inflammation, and infection (1). CCL3 shares 68% amino acid identity with CCL4 (MIP-1β) and 94% amino acid identity with LD78β (1). CCL3 is produced by activated monocytes, activated macrophages, NK cells, and T cells (1). There are two receptors for CCL3: CCR1 and CCR5 (1). CCL3 inhibits R5 HIV-1 infection by competing with the virus for its co-receptor, CCR5 (1). CCL3 possesses hematopoietic stem cell inhibitory activity, suppressing their proliferation, but has been shown to promote proliferation of more mature progenitors (2-4). CCL3 has been implicated in several forms of leukemia, in which malignant cells may lose responsiveness to CCL3 or produce high levels of CCL3 (2). CCL3 polymorphisms are associated with risk for the development of rheumatoid arthritis and ulcerative colitis (5,6). CCL3 expression is upregulated in the brains of patients with Alzheimer's disease (AD) with dementia, and reduced expression of CCL3 is observed in AD patients resilient to dementia (7).
- Menten, P. et al. (2002) Cytokine Growth Factor Rev 13, 455-81.
- Baba, T. and Mukaida, N. (2014) Mol Cell Oncol 1, e29899.
- Broxmeyer, H.E. et al. (1990) Blood 76, 1110-6.
- Broxmeyer, H.E. et al. (1989) J Exp Med 170, 1583-94.
- Zhang, R. et al. (2010) Int J Immunogenet 37, 273-8.
- Li, K. et al. (2009) Int J Colorectal Dis 24, 13-7.
- Barroeta-Espar, I. et al. (2019) Neurobiol Dis 121, 327-337.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.